Characteristics of participants in cohort 1
Characteristics . | IL-2 group, n = 42 . | Control group, n = 40 . |
|---|---|---|
| No. CD4 cells/μL (range) | 696 (108-1297)* | 328 (80-962) |
| No. CD8 cells/μL (range) | 1137 (437-2995)† | 750 (424-2404) |
| No. HIV-RNA log copies/mL (range) | 3.0 (2.7-5.4) | 2.8 (2.7-5.6) |
| No. patients with fewer than 500 HIV-RNA copies/mL (%) | 18/42 (43) | 20/40 (50) |
| HIV diagnosis, y (range) | 10 (2-15)‡ | 3 (0.5-15) |
| Percent CD4 T cells BrdU+ (range) | 0.141 (0.022-0.765)* | 0.209 (0.048-1.542) |
| Percent CD8 T cells BrdU+ (range) | 0.088 (0-0.530) | 0.129 (0.02-1.086) |
| Mos. since last IL-2 cycle (range) | 5 (1-22) | NA |
| Total no. of IL-2 cycles (range) | 11 (3-24) | NA |
Characteristics . | IL-2 group, n = 42 . | Control group, n = 40 . |
|---|---|---|
| No. CD4 cells/μL (range) | 696 (108-1297)* | 328 (80-962) |
| No. CD8 cells/μL (range) | 1137 (437-2995)† | 750 (424-2404) |
| No. HIV-RNA log copies/mL (range) | 3.0 (2.7-5.4) | 2.8 (2.7-5.6) |
| No. patients with fewer than 500 HIV-RNA copies/mL (%) | 18/42 (43) | 20/40 (50) |
| HIV diagnosis, y (range) | 10 (2-15)‡ | 3 (0.5-15) |
| Percent CD4 T cells BrdU+ (range) | 0.141 (0.022-0.765)* | 0.209 (0.048-1.542) |
| Percent CD8 T cells BrdU+ (range) | 0.088 (0-0.530) | 0.129 (0.02-1.086) |
| Mos. since last IL-2 cycle (range) | 5 (1-22) | NA |
| Total no. of IL-2 cycles (range) | 11 (3-24) | NA |